High Tech Pharm Co Ltd banner
H

High Tech Pharm Co Ltd
KOSDAQ:106190

Watchlist Manager
High Tech Pharm Co Ltd
KOSDAQ:106190
Watchlist
Price: 20 200 KRW 1.81% Market Closed
Market Cap: ₩214.7B

High Tech Pharm Co Ltd
Total Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

High Tech Pharm Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
H
High Tech Pharm Co Ltd
KOSDAQ:106190
Total Current Liabilities
₩12.5B
CAGR 3-Years
-27%
CAGR 5-Years
-14%
CAGR 10-Years
-1%
Yuhan Corp
KRX:000100
Total Current Liabilities
₩733.6B
CAGR 3-Years
19%
CAGR 5-Years
14%
CAGR 10-Years
7%
SK Biopharmaceuticals Co Ltd
KRX:326030
Total Current Liabilities
₩295.2B
CAGR 3-Years
22%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Total Current Liabilities
₩605.2B
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
-1%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Total Current Liabilities
₩106.6B
CAGR 3-Years
41%
CAGR 5-Years
35%
CAGR 10-Years
17%
C
Caregen Co Ltd
KOSDAQ:214370
Total Current Liabilities
₩8.4B
CAGR 3-Years
-7%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

High Tech Pharm Co Ltd
Glance View

Market Cap
214.7B KRW
Industry
Pharmaceuticals

HIGH TECH PHARM Co., Ltd. engages in the manufacture and sale of raw materials for injectable antibiotic products. The company is headquartered in Chungju, Chungcheongbuk-Do and currently employs 99 full-time employees. The company went IPO on 2010-07-28. CO., LTD. is a Korea-based company mainly engaged in the manufacture of antibiotic pharmaceutical ingredients for injections. The firm's products include sterile imipenem, sterile cilastatin sodium, sterile blended imipenem and cilastatin sodium, injectable sterile meropenem, injectable sterile panipenem, faropenem and others. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
12 186.04 KRW
Overvaluation 40%
Intrinsic Value
Price ₩20 200
H

See Also

What is High Tech Pharm Co Ltd's Total Current Liabilities?
Total Current Liabilities
12.5B KRW

Based on the financial report for Dec 31, 2025, High Tech Pharm Co Ltd's Total Current Liabilities amounts to 12.5B KRW.

What is High Tech Pharm Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-1%

Over the last year, the Total Current Liabilities growth was -34%. The average annual Total Current Liabilities growth rates for High Tech Pharm Co Ltd have been -27% over the past three years , -14% over the past five years , and -1% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett